Neumora Therapeutics to Participate in Upcoming Conferences in November
Neumora Therapeutics (Nasdaq: NMRA), a clinical-stage biopharmaceutical company focused on brain disease treatments, has announced its participation in two major healthcare conferences this November. The company will present at Guggenheim's Inaugural Healthcare Innovation Conference on November 13 at 3:00 p.m. ET in Boston, and at the Stifel 2024 Healthcare Conference on November 18 at 10:20 a.m. ET in New York. Both presentations will feature management fireside chats and will be available via live webcast on the company's website, with recordings archived for up to 30 days.
Neumora Therapeutics (Nasdaq: NMRA), un'azienda biofarmaceutica in fase clinica focalizzata sui trattamenti per le malattie cerebrali, ha annunciato la sua partecipazione a due importanti conferenze sanitarie questo novembre. L'azienda presenterà alla Conferenza Inaugurale sull'Innovazione Sanitaria di Guggenheim il 13 novembre alle 15:00 ET a Boston, e alla Conferenza Sanitaria Stifel 2024 il 18 novembre alle 10:20 ET a New York. Entrambe le presentazioni includeranno discussioni informali con la direzione e saranno disponibili tramite webcast dal vivo sul sito web dell'azienda, con registrazioni archiviate per un massimo di 30 giorni.
Neumora Therapeutics (Nasdaq: NMRA), una compañía biofarmacéutica en etapa clínica centrada en tratamientos para enfermedades cerebrales, ha anunciado su participación en dos importantes conferencias de salud este noviembre. La compañía presentará en la Conferencia Inaugural de Innovación en Salud de Guggenheim el 13 de noviembre a las 3:00 p.m. ET en Boston, y en la Conferencia de Salud Stifel 2024 el 18 de noviembre a las 10:20 a.m. ET en Nueva York. Ambas presentaciones incluirán charlas informales con la dirección y estarán disponibles a través de una transmisión en vivo en el sitio web de la compañía, con grabaciones archivadas por hasta 30 días.
Neumora Therapeutics (Nasdaq: NMRA)는 뇌 질환 치료에 중점을 둔 임상 단계의 생명공학 회사로, 이번 11월에 두 개의 주요 의료 회의에 참여한다고 발표했습니다. 회사는 11월 13일 오후 3시 ET에 보스턴에서 열리는 구겐하임의 첫 번째 의료 혁신 회의와 11월 18일 오전 10시 20분 ET에 뉴욕에서 열리는 스티펠 2024 의료 회의에서 발표를 진행합니다. 두 발표 모두 경영진과의 비공식 대화가 포함되며, 회사 웹사이트에서 실시간 웹캐스트를 통해 이용할 수 있으며, 30일 동안 녹화된 자료도 보관됩니다.
Neumora Therapeutics (Nasdaq: NMRA), une entreprise bio-pharmaceutique en phase clinique axée sur les traitements des maladies cérébrales, a annoncé sa participation à deux importantes conférences de santé ce mois de novembre. L'entreprise présentera à la Conférence Inaugurale sur l'Innovation Sanitaire de Guggenheim le 13 novembre à 15h00 ET à Boston, et à la Conférence de Santé Stifel 2024 le 18 novembre à 10h20 ET à New York. Les deux présentations comprendront des discussions informelles avec la direction et seront disponibles en direct via un webinaire sur le site web de l'entreprise, avec des enregistrements archivés jusqu'à 30 jours.
Neumora Therapeutics (Nasdaq: NMRA), ein biopharmazeutisches Unternehmen in der klinischen Phase, das sich auf Behandlungen für Erkrankungen des Gehirns konzentriert, hat seine Teilnahme an zwei bedeutenden Gesundheitskonferenzen im November bekannt gegeben. Das Unternehmen wird am 13. November um 15:00 Uhr ET in Boston auf der Ersten Gesundheitsinnovationskonferenz von Guggenheim und am 18. November um 10:20 Uhr ET in New York auf der Stifel Gesundheitskonferenz 2024 präsentieren. Beide Präsentationen umfassen informelle Gespräche mit dem Management und werden über einen Live-Webcast auf der Unternehmenswebsite verfügbar sein, wobei Aufzeichnungen bis zu 30 Tage archiviert werden.
- None.
- None.
WATERTOWN, Mass., Nov. 06, 2024 (GLOBE NEWSWIRE) -- Neumora Therapeutics, Inc. (Nasdaq: NMRA), a clinical-stage biopharmaceutical company with a therapeutics pipeline consisting of seven clinical and pre-clinical brain disease programs, today announced that the Company will participate in two investor conferences in November:
- Guggenheim’s Inaugural Healthcare Innovation Conference: Members of management will participate in a fireside chat on Wednesday, November 13, 2024, at 3:00 p.m. ET in Boston, MA.
- Stifel 2024 Healthcare Conference: Members of management will participate in a fireside chat on Monday, November 18, 2024, at 10:20 a.m. ET in New York, NY.
A live webcast of each event will be available on the events and presentations section of the Company’s website at www.neumoratx.com. A replay of the webcasts will be available following the completion of the event and will be archived for up to 30 days.
About Neumora
Neumora Therapeutics, Inc. is a clinical-stage biopharmaceutical company founded to confront the global brain disease crisis by taking a fundamentally different approach to the way treatments for brain diseases are developed. Our therapeutic pipeline currently consists of seven clinical and preclinical neuroscience programs that target novel mechanisms of action for a broad range of underserved neuropsychiatric disorders and neurodegenerative diseases. Our work is supported by an integrated suite of translational, clinical, and computational tools to generate insights that can enable precision medicine approaches. Neumora’s mission is to redefine neuroscience drug development by bringing forward the next generation of novel therapies that offer improved treatment outcomes and quality of life for patients suffering from brain diseases.
Neumora Contact:
Helen Rubinstein
315-382-3979
Helen.Rubinstein@neumoratx.com
FAQ
When is Neumora Therapeutics (NMRA) presenting at the Guggenheim Healthcare Conference?
When is Neumora Therapeutics (NMRA) presenting at the Stifel Healthcare Conference?
How long will Neumora Therapeutics (NMRA) conference webcasts be available?
How many clinical and pre-clinical programs does Neumora Therapeutics (NMRA) have?
